Neurocrine Biosciences
NBIX
#1310
Rank
A$24.69 B
Marketcap
A$245.57
Share price
-0.29%
Change (1 day)
19.55%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): A$9.99

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$9.61. In 2025 the company made an earnings per share (EPS) of A$6.90 an increase over its 2024 EPS that were of A$4.84.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$9.9944.85%
2025A$6.9042.6%
2024A$4.8433.07%
2023A$3.6457.76%
2022A$2.3069.47%
2021A$1.36-78.21%
2020A$6.24990%
2019A$0.5781.82%
2018A$0.31-113.5%
2017A-$2.330.62%
2016A-$2.3257.28%
2015A-$1.4725.61%
2014A-$1.1718.84%
2013A-$0.99-1085.71%
2012A$0.10

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
A$1.88-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$2.94-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$40.40 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$1.32-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$2.91-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$5.01-47.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
A-$42.80-545.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.73-71.62%๐Ÿ‡ฌ๐Ÿ‡ง UK